semaglutide salt side effects Top 5 Common and How to Minimize Them FDA Gives Ozempic New Side

Anderson, B

The Policy: Medicare's BALANCE Model In July 2026, Medicare launches the GLP-1 Bridge, an interim six-month pilot covering semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for beneficiaries with a BMI of 30 or higher, or BMI of 27 or higher with an obesity-related comorbidity (diabetes, cardiovascular disease, hypertension)

There was no significant difference between these two treatment strategies overall (HR 0.88, 95% CI 0.68 to 1.14, p = 0.35)

To be fully transparent, one thing that shows up in independent ingredient reviews is the small amount of ethanol in the formula, which is flagged for caution on its own, though here it's used in a tiny quantity as a natural preservative and carrier, not as a primary ingredient